HUMAN EVIDENCE
Clinical trials and observational studies.
THE NEUROSCIENCE RESEARCH FILE
The science
of craving.
An independent look at what GLP-1 research does—and does not—tell us about alcohol use, nicotine, and reward circuitry.
Independent editorial guidance. Sponsored links clearly identified. No prescription guarantees.
RESEARCH BEFORE REFERRALS ↓
INDEPENDENT EDITORIAL RESEARCHVISIBLE SPONSORED LINKSREAL-WORLD BILLING CONTEXT
THE EDITORIAL STANDARD
Inside the research
Early findings are worth studying. They are not a treatment promise.
WHAT IS UNKNOWN
Open questions, limitations and uncertainty.
NO APPROVED INDICATION
GLP-1 drugs are not FDA-approved to treat addiction.
THE READING ROOM
Read past the headline.
READING 01 / THE LIBRARY
Ozempic and Alcohol: What the First Clinical Trial Actually Found
Read article ↗READING 02 / THE LIBRARY606,000 Veterans, One Clear Signal: The BMJ Study That Linked GLP-1 Medications to Lower Addiction Risk A
Read article ↗READING 03 / THE LIBRARYBeyond Substances: Can GLP-1 Drugs Help With Gambling, Shopping, and Compulsive Behaviors?
Read article ↗SEPARATE WEIGHT-MANAGEMENT REFERRALS / SPONSORED
Research and treatment are different subjects. Paid weight-management partners do not provide approved GLP-1 addiction treatment.
Care questions, separately.
Critical distinction: GLP-1 medicines are not FDA-approved treatments for addiction. Early research is not evidence of a prescription indication. The following links, if displayed, concern separate weight-management services.
THE COMPLETE SPONSORED DIRECTORY
Compare the details.
Current public provider prices checked October 23, 2026. Amounts and billing cycles vary; verify the exact checkout quote. Disagreements between provider pages are disclosed below.
PRICING BASIS · Each card now separates what is due upfront, the recurring charge, whether medication is included, and a comparable time period. A starting rate, prepaid bundle and care-only membership are not interchangeable. Source checked October 23, 2026; checkout may differ.
PARTNER / 01CARE ONLY / MEDICINE EXTRA
Sesame Care
Care only; medication billed separately
$59care membership / calendar month
$59/month requires a 12-month care commitment; month-to-month care is $99/month. Medications are separate, advertised from $149/month, so a combined minimum could start near $208/month if eligible.
- Due initially
- Care billed per chosen commitment
- After / ongoing
- $59/mo annual plan or $99/mo flexible
- Medicine
- NOT INCLUDED; from $149 extra
- Comparable basis
- Care-only; ~$208+ combined if available
PARTNER / 02MONTHLY START / DOSE-DEPENDENT
Oak Longevity
GLP-1 plan; dosage affects final price
$250per month GLP-1 listing
Oak checkout advertises GLP-1 at $250/month and dual GIP/GLP-1 at $300/month. Its other page says programs start at $190/month. Dose increases can raise charges by about $50–$75 per step; verify plan and cycle.
- Due initially
- Usually 1 month; 3-month Rx upfront
- After / ongoing
- From $250/mo, dose-dependent
- Medicine
- Included in treatment price subject to plan
- Comparable basis
- $250 / month ENTRY ONLY
PARTNER / 03MEDICATION + REQUIRED MEMBERSHIP
Ivim Health
Compounded semaglutide + required membership
$149.99+per-month equivalent, two charges
$74.99 monthly membership PLUS semaglutide medication advertised from $75/month equivalent on an upfront-paid plan. Minimum combined equivalent $149.99/month, with more due initially for prepaid medication.
- Due initially
- Medication prepayment + membership
- After / ongoing
- $74.99/mo + medication from $75/mo equivalent
- Medicine
- Extra prepaid medication charge
- Comparable basis
- $149.99+ / month combined equivalent
Important: Prices and program access may change. Compounded GLP-1 drugs are not FDA-approved. A medical evaluation is required; a prescription is not guaranteed. Some links are paid affiliate referrals and may earn this publication a commission. Check the current program terms, licensure, and fees directly before payment.